Key Events This Week
Jan 19: Stock hits 52-week low and lower circuit at Rs.8.16
Jan 20: Lower circuit hit again at fresh 52-week low of Rs.7.76
Jan 21: New 52-week low of Rs.7.38 with lower circuit triggered
Jan 22: Stock closes at 52-week low Rs.7.00, lower circuit hit at Rs.7.02
Jan 23: Slight recovery to Rs.7.31 (+4.43%) but still below week open
Monday, 19 January 2026: Lower Circuit and 52-Week Low Amid Prolonged Decline
Vivimed Labs opened the week on a weak note, closing at Rs.8.14, down 4.91% from the previous close, and hitting a fresh 52-week low. The stock triggered its lower circuit limit at Rs.8.16, reflecting intense selling pressure and a lack of buying interest. This marked the 18th consecutive session of decline, with the stock losing approximately 66% of its value over this period. The broader Sensex also declined 0.49%, but Vivimed Labs’ underperformance was stark, highlighting company-specific challenges.
Investor sentiment was dampened by the absence of recent financial disclosures and deteriorating fundamentals, including a high Debt to EBITDA ratio of 12.57 times and a negative half-year PAT of Rs.-281.57 crores. The stock traded below all key moving averages, signalling sustained bearish momentum.
Tuesday, 20 January 2026: Continued Lower Circuit Hits and Deepening Downtrend
The downtrend intensified as Vivimed Labs again hit its lower circuit limit, closing at Rs.7.74, down 4.91% on the day and marking a new 52-week low. The stock’s loss over 19 sessions reached 67.64%, with delivery volumes plunging sharply, indicating waning long-term investor participation. Despite moderate liquidity with a traded volume of 4.76 lakh shares, the stock’s micro-cap status and weak fundamentals continued to weigh heavily on price action.
The Pharmaceuticals & Drugs sector declined only 0.76%, and the Sensex fell 1.82%, underscoring the stock’s relative weakness. The Mojo Grade remained a Strong Sell with a low Mojo Score of 24.0, reflecting deteriorated fundamentals and negative market sentiment.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Wednesday, 21 January 2026: New 52-Week Low and Lower Circuit Amid Panic Selling
Vivimed Labs’ share price fell further to Rs.7.38, down 4.9% and hitting the lower circuit band once again. This marked the 20th consecutive day of losses, with the stock declining approximately 69.26% over this period. The stock underperformed its sector by 5.52% amid intense selling pressure and panic among investors. Delivery volumes surged, suggesting forced liquidation or panic selling by long-term holders.
Despite the broader Sensex dipping only marginally by 0.47%, Vivimed Labs’ micro-cap status and weak liquidity exacerbated price volatility. The stock remained below all key moving averages, confirming a strong bearish trend. The company’s financial health remained fragile, with a high debt-equity ratio of 9.60 times and a modest average ROE of 1.75%.
Thursday, 22 January 2026: Persistent Decline and Lower Circuit at Rs.7.02
The stock continued its downward spiral, closing at Rs.7.00, down 4.89%, and hitting a new 52-week low. It triggered the lower circuit limit at Rs.7.02 amid heavy selling and panic exits. This marked 21 consecutive sessions of losses, with a cumulative decline of 70.76%. The broader market showed resilience with the Sensex gaining 0.67% and the pharmaceuticals sector rising 1.68%, highlighting company-specific difficulties.
Financial metrics remained concerning, with a negative PAT of Rs.-281.57 crores and a low debtors turnover ratio of 2.44 times, indicating operational stress. The Mojo Grade of Strong Sell and a Mojo Score of 24.0 reflected the deteriorating fundamentals and weak price momentum.
Holding Vivimed Labs from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Friday, 23 January 2026: Minor Recovery but Weekly Losses Persist
Vivimed Labs closed the week at Rs.7.31, gaining 4.43% on the day but still well below the week’s opening price. The slight rebound followed four consecutive days of sharp declines and multiple lower circuit hits. The Sensex fell 1.33% on the day, while the stock’s modest recovery did little to offset the week’s overall 14.60% loss from Rs.8.56 to Rs.7.31.
The stock remains in a precarious position, trading below all major moving averages and burdened by weak financials and low investor confidence. The micro-cap nature and limited liquidity continue to amplify volatility and downside risk.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-01-19 | Rs.8.14 | -4.91% | 36,650.97 | -0.49% |
| 2026-01-20 | Rs.7.74 | -4.91% | 35,984.65 | -1.82% |
| 2026-01-21 | Rs.7.36 | -4.91% | 35,815.26 | -0.47% |
| 2026-01-22 | Rs.7.00 | -4.89% | 36,088.66 | +0.76% |
| 2026-01-23 | Rs.7.31 | +4.43% | 35,609.90 | -1.33% |
Key Takeaways
Persistent Downtrend: Vivimed Labs’ stock has been in a steep decline for over three weeks, losing more than 70% from recent highs and hitting multiple 52-week lows.
Repeated Lower Circuit Hits: The stock triggered lower circuit limits on four separate days, signalling intense selling pressure and an imbalance between supply and demand.
Weak Financials and High Leverage: Elevated Debt to EBITDA ratio (12.57 times), negative PAT of Rs.-281.57 crores, and low ROE of 1.75% highlight fundamental challenges.
Micro-Cap and Liquidity Constraints: With a market capitalisation around Rs.64 crore and limited free float, the stock is vulnerable to sharp price swings and low trading volumes.
Negative Analyst Sentiment: The Mojo Grade of Strong Sell and a low Mojo Score of 24.0 reflect deteriorated fundamentals and weak price momentum.
Sector Divergence: While the Pharmaceuticals & Drugs sector showed modest gains during the week, Vivimed Labs’ underperformance underscores company-specific issues.
Minor Recovery on Final Day: A small bounce on 23 January did little to reverse the overall negative trend, with the stock still down 14.60% for the week.
Conclusion
Vivimed Labs’ share price performance during the week of 19-23 January 2026 paints a picture of sustained weakness driven by deteriorating fundamentals, high leverage, and persistent investor pessimism. The stock’s repeated lower circuit hits and sharp declines contrast with a relatively stable pharmaceuticals sector and broader market. Despite a slight recovery on the final trading day, the stock remains in a pronounced downtrend, trading well below all key moving averages and burdened by poor financial metrics. The micro-cap status and limited liquidity further exacerbate volatility and risk. Investors should remain cautious and closely monitor any fundamental developments or changes in market sentiment before considering exposure to this stock.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
